BiomX Inc. (NYSE:PHGE) Q1 2025 Earnings Conference Call May 15, 2025 2:00 PM ET Company Participants Marina Wolfson - CFO Jonathan Solomon - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Yale Jen - Laidlaw & Company Operator Greetings and welcome to the BiomX First Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode. The question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference ...

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 82-3364020 | | --- | --- | | (State or other jurisdict ...

BiomX (PHGE) Q1 2025 Earnings Call May 15, 2025 02:00 PM ET Speaker0 Greetings, and welcome to the BioMix First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I will now turn the conference over to Marina Wolfson, Chief Financial Officer. Thank you. You may begin. Speaker1 Thank you, and welcome to the Bionics conference ca ...

Financial Performance - The net loss for Q1 2025 was $7.7 million, significantly lower than the $17.3 million loss in Q1 2024, attributed to changes in the fair value of warrants[11]. - The net loss for the three months ended March 31, 2025, was $7,659 million, a decrease from a net loss of $17,327 million in the same period of 2024, reflecting an improvement of 55.7%[24]. - Basic and diluted loss per share of Common Stock decreased to $0.33 for the three months ended March 31, 2025, compared to $2.78 for the same period in 2024, showing a significant reduction in loss per share[24]. - The company reported a loss before tax of $7,658 million for the three months ended March 31, 2025, down from $17,322 million in the same period of 2024, reflecting a decrease of 55.7%[24]. - Operating loss for the three months ended March 31, 2025, was $7,756 million, compared to $6,785 million for the same period in 2024, indicating an increase of 14.3%[24]. Research and Development - Research and development expenses for Q1 2025 were $5.3 million, an increase from $4.1 million in Q1 2024, driven by preparations for the Phase 2b trial of BX004 and increased expenses for the BX211 trial[9]. - Research and development expenses for the three months ended March 31, 2025, were $5,250 million, up from $4,105 million in the same period of 2024, indicating an increase of 27.8%[24]. - BiomX announced positive topline results from the Phase 2 trial of BX211, showing a statistically significant reduction in ulcer size with a p-value of 0.046 at week 12[6]. - BX211 demonstrated a greater than 40% reduction in ulcer size compared to placebo by week 10, with significant improvements in ulcer depth and area expansion[14]. - The company is planning a Phase 2/3 clinical trial for BX211 pending feedback from the FDA[6]. - The company anticipates the Phase 2b readout of BX004 for cystic fibrosis in Q1 2026, supported by recent financing activities[7]. Financial Position - BiomX reported a cash balance of $21.2 million as of March 31, 2025, up from $18.0 million at the end of 2024, primarily due to financing activities[8]. - BiomX's cash resources are estimated to be sufficient to fund operations into Q1 2026[8]. - As of March 31, 2025, total current assets increased to $23,533 million from $20,520 million as of December 31, 2024, representing a growth of 14.6%[20]. - Total stockholders' equity increased to $24,499 million as of March 31, 2025, from $24,148 million as of December 31, 2024, marking a rise of 1.5%[20]. - Total current liabilities decreased to $7,021 million as of March 31, 2025, from $8,267 million as of December 31, 2024, a reduction of 15.1%[20]. - Non-current liabilities rose to $14,134 million as of March 31, 2025, from $10,818 million as of December 31, 2024, an increase of 30.5%[20]. Shareholder Information - The weighted average number of shares used in computing basic and diluted loss per share increased significantly to 23,103,105 for the three months ended March 31, 2025, compared to 6,229,228 for the same period in 2024[24].

In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report topline results in Q1 2026 In April 2025, shareholders approved exercise of warrants issued in $12 million in financings announced in February 2025; funds expected to provide runway through topline Phase 2b results for BX004 trial The Company will host a conference call and webcast today at 2:00 PM ...

NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates. To participate in the conference call, please dial 1-877- ...

Group 1: Stock Performance and Technical Analysis - Shares of BiomX Inc. (PHGE) have lost 7.9% over the past two weeks, but a hammer chart pattern formed in the last trading session suggests potential support and a possible trend reversal [1] - The hammer pattern indicates a nearing bottom with potential exhaustion of selling pressure, which is supported by rising optimism among Wall Street analysts regarding the company's future earnings [2][7] - The hammer chart pattern is characterized by a small candle body and a long lower wick, signaling that bears may have lost control over the price during a downtrend [4][5] Group 2: Earnings Estimates and Analyst Ratings - There has been a 34.9% increase in the consensus EPS estimate for the current year over the last 30 days, indicating that sell-side analysts expect better earnings than previously predicted [8] - PHGE currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9] - The positive trend in earnings estimate revisions is a bullish indicator that may lead to price appreciation in the near term [7][9]

BiomX (PHGE) Q4 2024 Earnings Call April 01, 2025 12:22 PM ET Company Participants Marina Wolfson - CFO & SecretaryJonathan Eitan Solomon - CEO and Board MemberJoe Pantginis - Managing Director Conference Call Participants Yale Jen - Senior Managing Director & Senior Biotech Analyst Operator Greetings, and welcome to today's BioMx Investor Presentation. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference ...

NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced that, as previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the Securities and Exchange Commission on March 25, 2025, the audit opinion contained a going concern qualification from the Company's independe ...

The Company will host a conference call and webcast today at 9:00 AM ET, followed by a Key Opinion Leader (KOL) event on April 3, 2025, at 11:00 AM ET to discuss the results "We believe these data represent one of the strongest demonstrations to date of the therapeutic potential of phage therapy. We are grateful to all the patients who participated, and the treating teams who enrolled patients into the study, as well as the continued and ongoing support from the U.S. Defense Health Agency (DHA) for this pro ...